Health Professionals – Melanoma Research Victoria https://melanomaresearchvic.com.au Fri, 25 Sep 2020 02:59:56 +0000 en-US hourly 1 https://melanomaresearchvic.com.au/wp-content/uploads/2017/12/cropped-favicon-32x32.png Health Professionals – Melanoma Research Victoria https://melanomaresearchvic.com.au 32 32 Emerging options for high-risk melanoma https://melanomaresearchvic.com.au/emerging-options-for-high-risk-melanoma Fri, 25 Sep 2020 02:58:50 +0000 https://melanomaresearchvic.com.au/?p=15684 An ongoing study is attempting to build on what researchers have learned in recent years regarding neoadjuvant approaches to immunotherapy for high-risk melanoma.

The post Emerging options for high-risk melanoma appeared first on Melanoma Research Victoria.

]]>
Source: Dermatology Times, August 2020

An ongoing study is attempting to build on what researchers have learned in recent years regarding neoadjuvant approaches to immunotherapy for high-risk melanoma.

With the increasing number of approved immunotherapies and targeted therapies for patients with stage 3 melanoma, accurate pathologic microstaging assumes increasing importance, says Giorgos Karakousis, M.D., associate professor of surgery at the Hospital of the University of Pennsylvania, Philadelphia.

“There have been ongoing discussions about the role and utility of sentinel lymph node (SLN) biopsy in patients with melanoma. But more so now than before, where a large part of the procedure’s value was prognostic, there is value in terms of helping guide decisions about effective adjuvant therapies,” he says.

READ THE ORIGINAL FULL ARTICLE

The post Emerging options for high-risk melanoma appeared first on Melanoma Research Victoria.

]]>
Garutti Examines Advantages of Neoadjuvant Approaches in Melanoma https://melanomaresearchvic.com.au/garutti-examines-advantages-of-neoadjuvant-approaches-in-melanoma Fri, 25 Sep 2020 02:56:01 +0000 https://melanomaresearchvic.com.au/?p=15682 The use of adjuvant therapies in melanoma could offer superior efficacy compared to what is currently provided by adjuvant therapies alone, with some preclinical data pointing to increased clinical benefit within this patient population, according to Mattia Garutti, MD.

The post Garutti Examines Advantages of Neoadjuvant Approaches in Melanoma appeared first on Melanoma Research Victoria.

]]>
Source: OncLive, August 2020

The use of adjuvant therapies in melanoma could offer superior efficacy compared to what is currently provided by adjuvant therapies alone, with some preclinical data pointing to increased clinical benefit within this patient population, according to Mattia Garutti, MD.

“Especially in [patients with] stage III melanoma, the risk of relapse is really high,” said Garutti. “We need different strategies to increase cure rates for our patients. Neoadjuvant therapies in melanoma represent an exciting area of research. In other [diseases], such as breast cancer, the shift from the adjuvant to neoadjuvant therapy [has become] a gold standard. In melanoma, this shift is expected in the near future.”

Despite the advances that have been made with adjuvant therapies in recent years, patients with stage III melanoma still are at significant risk for relapse, Garutti and colleagues, wrote in a recent literature review.

READ THE ORIGINAL FULL ARTICLE

The post Garutti Examines Advantages of Neoadjuvant Approaches in Melanoma appeared first on Melanoma Research Victoria.

]]>
Melanoma ‘calculator’ for skin cancer risk https://melanomaresearchvic.com.au/melanoma-calculator-for-skin-cancer-risk Fri, 25 Sep 2020 02:49:54 +0000 https://melanomaresearchvic.com.au/?p=15680 Australians will now be able to determine their likelihood of developing melanoma in under a minute with a new lifetime risk ‘calculator’.

The post Melanoma ‘calculator’ for skin cancer risk appeared first on Melanoma Research Victoria.

]]>
Source: The Canberra Times, August 2020

Researchers at Melanoma Institute Australia have developed the online tool, and hope it will save lives by sparking early conversations between at-risk Australians and their doctors.

“No risk prediction is going to be absolutely perfect, but this is much better than anything else that’s available,” the institute’s co-medical director Richard Scolyer told AAP.

READ THE ORIGINAL FULL ARTICLE

The post Melanoma ‘calculator’ for skin cancer risk appeared first on Melanoma Research Victoria.

]]>
Dr. Long on the Rationale for the Phase 3 COMBI-i Trial in BRAF V600¬–Mutant Melanoma https://melanomaresearchvic.com.au/dr-long-on-the-rationale-for-the-phase-3-combi-i-trial-in-braf-v600%c2%ac-mutant-melanoma Thu, 24 Sep 2020 07:51:14 +0000 https://melanomaresearchvic.com.au/?p=15663 Georgina Long, BSc, PhD, MBBS, FRACP, co-medical director, Melanoma Institute Australia (MIA), chair of Melanoma Medical Oncology and Translational Research, MIA and Royal North Shore Hospital, University of Sydney, discusses the rationale for the phase 3 COMBI-i trial in BRAF V600­–mutant melanoma.

The post Dr. Long on the Rationale for the Phase 3 COMBI-i Trial in BRAF V600¬–Mutant Melanoma appeared first on Melanoma Research Victoria.

]]>
Source: OncLive, August 2020

 

Georgina Long, BSc, PhD, MBBS, FRACP, co-medical director, Melanoma Institute Australia (MIA), chair of Melanoma Medical Oncology and Translational Research, MIA and Royal North Shore Hospital, University of Sydney, discusses the rationale for the phase 3 COMBI-i trial in BRAF V600­–mutant melanoma.

The COMBI-i study evaluated the combination of spartalizumab, dabrafenib (Tafinlar), and trametinib (Mekinist), says Long.

Findings from parts 1 and 2 of the phase 3 trial were presented during the 2020 ASCO Virtual Scientific Program and showed encouraging clinical activity and tolerability with the novel triplet.

READ THE ORIGINAL FULL ARTICLE

The post Dr. Long on the Rationale for the Phase 3 COMBI-i Trial in BRAF V600¬–Mutant Melanoma appeared first on Melanoma Research Victoria.

]]>
The ongoing racial disparities in melanoma: an analysis of the Surveillance, Epidemiology, and End Results database (SEER) database (1975-2016) https://melanomaresearchvic.com.au/the-ongoing-racial-disparities-in-melanoma-an-analysis-of-the-surveillance-epidemiology-and-end-results-database-seer-database-1975-2016 Wed, 23 Sep 2020 06:04:41 +0000 https://melanomaresearchvic.com.au/?p=15644 Although the majority of cutaneous melanoma patients are non-Hispanic white (NHW), minorities consistently suffer worse melanoma specific survival (MSS). Much of the literature comes from analyses of registries from the 1990s and 2000s.

The post The ongoing racial disparities in melanoma: an analysis of the Surveillance, Epidemiology, and End Results database (SEER) database (1975-2016) appeared first on Melanoma Research Victoria.

]]>
Source: urbanhealthToday, August 2020

Although the majority of cutaneous melanoma patients are non-Hispanic white (NHW), minorities consistently suffer worse melanoma specific survival (MSS). Much of the literature comes from analyses of registries from the 1990s and 2000s.

OBJECTIVE: To evaluate whether and to what degree racial disparity in MSS persists since 2010.

METHODS: We analyzed 381,035 patients from the Surveillance, Epidemiology, and End Results (SEER) registry. Race categories included Hispanic, NHW, non-Hispanic black (NHB), non-Hispanic Asian or Pacific Islander (NHAPI), and non-Hispanic American Indian/Alaska Native (NHAIAN).

READ THE ORIGINAL FULL ARTICLE

The post The ongoing racial disparities in melanoma: an analysis of the Surveillance, Epidemiology, and End Results database (SEER) database (1975-2016) appeared first on Melanoma Research Victoria.

]]>
Scientists identify key driver in BRAF inhibitor resistant melanoma https://melanomaresearchvic.com.au/scientists-identify-key-driver-in-braf-inhibitor-resistant-melanoma Mon, 21 Sep 2020 07:46:22 +0000 https://melanomaresearchvic.com.au/?p=15637 Targeted therapy with BRAF-MEK inhibitors is an effective treatment for patients with advanced melanoma that cannot be surgically removed or has spread to other areas of the body.

The post Scientists identify key driver in BRAF inhibitor resistant melanoma appeared first on Melanoma Research Victoria.

]]>
Source: News Medical Life Sciences, September 2020

Targeted therapy with BRAF-MEK inhibitors is an effective treatment for patients with advanced melanoma that cannot be surgically removed or has spread to other areas of the body.

However, many patients become resistant to the therapy, and this can often lead to further metastasis. Moffitt Cancer Center researchers who helped develop this type of combination therapy are now working to better understand what leads to this resistance in hopes of developing ways to overcome it.

In a new article published in the Journal of Investigative Dermatology, Moffitt researchers identify erythropoietin-producing hepatocellular receptor A2 (EphA2) as a driver of metastasis and BRAF-MEK inhibitor resistance in melanoma.

READ THE ORIGINAL FULL ARTICLE

The post Scientists identify key driver in BRAF inhibitor resistant melanoma appeared first on Melanoma Research Victoria.

]]>
Moffitt researchers identify metastasis driver in BRAF inhibitor resistant melanoma https://melanomaresearchvic.com.au/moffitt-researchers-identify-metastasis-driver-in-braf-inhibitor-resistant-melanoma Mon, 21 Sep 2020 07:42:11 +0000 https://melanomaresearchvic.com.au/?p=15635 TAMPA, Fla. — Targeted therapy with BRAF-MEK inhibitors is an effective treatment for patients with advanced melanoma that cannot be surgically removed or has spread to other areas of the body.

The post Moffitt researchers identify metastasis driver in BRAF inhibitor resistant melanoma appeared first on Melanoma Research Victoria.

]]>
Source: Science Codex, September 2020

TAMPA, Fla. — Targeted therapy with BRAF-MEK inhibitors is an effective treatment for patients with advanced melanoma that cannot be surgically removed or has spread to other areas of the body.

However, many patients become resistant to the therapy, and this can often lead to further metastasis.

Moffitt Cancer Center researchers who helped develop this type of combination therapy are now working to better understand what leads to this resistance in hopes of developing ways to overcome it.

READ THE ORIGINAL FULL ARTICLE

The post Moffitt researchers identify metastasis driver in BRAF inhibitor resistant melanoma appeared first on Melanoma Research Victoria.

]]>
Dr. Blank on the OpACIN, OpACIN-neo Trials in Stage III Macroscopic Melanoma https://melanomaresearchvic.com.au/dr-blank-on-the-opacin-opacin-neo-trials-in-stage-iii-macroscopic-melanoma Fri, 18 Sep 2020 08:21:01 +0000 https://melanomaresearchvic.com.au/?p=15628 Christian U. Blank, MD, PhD, a medical oncologist in the Division of Immunology at the Netherlands Cancer Institute, discusses the OpACIN and OPACIN-neo trials examining ipilimumab (Yervoy) plus nivolumab (Opdivo) in stage III macroscopic melanoma.

The post Dr. Blank on the OpACIN, OpACIN-neo Trials in Stage III Macroscopic Melanoma appeared first on Melanoma Research Victoria.

]]>
Source: OncLive, September 2020

Christian U. Blank, MD, PhD, a medical oncologist in the Division of Immunology at the Netherlands Cancer Institute, discusses the OpACIN and OPACIN-neo trials examining ipilimumab (Yervoy) plus nivolumab (Opdivo) in stage III macroscopic melanoma.

In the phase 1b OpACIN trial, neoadjuvant ipilimumab plus nivolumab was compared with adjuvant ipilimumab plus nivolumab, while the subsequent OpACIN-neo trial evaluated 3 different dosing schedules of neoadjuvant ipilimumab plus nivolumab.

As the OpACIN study looked at a very small patient population, the OpACIN-neo study was conducted, says Blank.

READ THE ORIGINAL FULL ARTICLE

The post Dr. Blank on the OpACIN, OpACIN-neo Trials in Stage III Macroscopic Melanoma appeared first on Melanoma Research Victoria.

]]>
Targeted combination immunotherapy improved survival in stage III melanoma https://melanomaresearchvic.com.au/targeted-combination-immunotherapy-improved-survival-in-stage-iii-melanoma Thu, 17 Sep 2020 07:52:54 +0000 https://melanomaresearchvic.com.au/?p=15624 Response: Based on molecular biology analysis, a substantial proportion of melanomas are driven by mutations of BRAF resulting in an ongoing growth activating signal. Based on the key role of BRAF several multiple kinase molecules have been developed in order to target this crucial pathway. These medications have shown to improve progression free survival and […]

The post Targeted combination immunotherapy improved survival in stage III melanoma appeared first on Melanoma Research Victoria.

]]>
Source: MedicalResearch.com, September 2020

MedicalResearch.com: What is the background for this study?

Response: Based on molecular biology analysis, a substantial proportion of melanomas are driven by mutations of BRAF resulting in an ongoing growth activating signal. Based on the key role of BRAF several multiple kinase molecules have been developed in order to target this crucial pathway. These medications have shown to improve progression free survival and overall survival in advanced metastatic melanoma.

Because there is a tendency for improved outcome in patients with low tumor burden, combined targeted therapy using Dabrafenib and Trametinib have been investigated in the adjuvant (after complete surgical resection) setting in stage III melanoma. And the 5 year data are now available in the New England Journal of Medicine.

READ THE ORIGINAL FULL ARTICLE

The post Targeted combination immunotherapy improved survival in stage III melanoma appeared first on Melanoma Research Victoria.

]]>
Adjuvant therapy in stage IIIA melanoma: Cost vs Benefit of gene profiling https://melanomaresearchvic.com.au/adjuvant-therapy-in-stage-iiia-melanoma-cost-vs-benefit-of-gene-profiling Thu, 17 Sep 2020 07:52:53 +0000 https://melanomaresearchvic.com.au/?p=15626 Response: Indications for adjuvant therapy for resected, high-risk melanoma is a controversial and rapidly-evolving topic in melanoma treatment.

The post Adjuvant therapy in stage IIIA melanoma: Cost vs Benefit of gene profiling appeared first on Melanoma Research Victoria.

]]>
Source: MedicalResearch.com, September 2020

MedicalResearch.com: What is the background for this study?

Response: Indications for adjuvant therapy for resected, high-risk melanoma is a controversial and rapidly-evolving topic in melanoma treatment.

Immunotherapy treatments targeting PD-1 have significantly improved survival in advanced-stage disease, but the magnitude of survival benefit in stage III disease–particularly stage IIIA–remains unclear.

Recently, 31-GEP (a gene expression profiling assay) has been studied as a risk-stratifying tool to identify patients who are at higher risk for systemic recurrence. Ideally such a tool could identify patients most likely to benefit from immunotherapy treatment in the adjuvant setting (when all visible disease has been removed).

READ THE ORIGINAL FULL ARTICLE

The post Adjuvant therapy in stage IIIA melanoma: Cost vs Benefit of gene profiling appeared first on Melanoma Research Victoria.

]]>